Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

681 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiomics in prostate cancer: an up-to-date review.
Ferro M, de Cobelli O, Musi G, Del Giudice F, Carrieri G, Busetto GM, Falagario UG, Sciarra A, Maggi M, Crocetto F, Barone B, Caputo VF, Marchioni M, Lucarelli G, Imbimbo C, Mistretta FA, Luzzago S, Vartolomei MD, Cormio L, Autorino R, Tătaru OS. Ferro M, et al. Among authors: autorino r. Ther Adv Urol. 2022 Jul 4;14:17562872221109020. doi: 10.1177/17562872221109020. eCollection 2022 Jan-Dec. Ther Adv Urol. 2022. PMID: 35814914 Free PMC article. Review.
Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial.
Di Lorenzo G, Autorino R, De Laurentiis M, Forestieri V, Romano C, Prudente A, Giugliano F, Imbimbo C, Mirone V, De Placido S. Di Lorenzo G, et al. Among authors: autorino r. Cancer Biol Ther. 2007 Mar;6(3):313-7. doi: 10.4161/cbt.6.3.3664. Epub 2007 Mar 6. Cancer Biol Ther. 2007. PMID: 17327701 Clinical Trial.
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
Di Lorenzo G, Autorino R, Perdonà S, De Laurentiis M, D'Armiento M, Cancello G, Mirone V, Imbimbo C, Longo N, Altieri V, Tortora G, Figg WD, De Placido S. Di Lorenzo G, et al. Among authors: autorino r. Eur Urol. 2007 Oct;52(4):1020-7. doi: 10.1016/j.eururo.2007.02.060. Epub 2007 Mar 7. Eur Urol. 2007. PMID: 17360103 Clinical Trial.
Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients.
Di Lorenzo G, Cartenì G, Autorino R, Gonnella A, Perdonà S, Ferro M, Longo N, Rescigno P, Doria F, Faiella A, Altieri V, Palmieri G, Imbimbo C, Mirone V, De Placido S. Di Lorenzo G, et al. Among authors: autorino r. Anticancer Drugs. 2009 Apr;20(4):277-80. doi: 10.1097/CAD.0b013e328329a293. Anticancer Drugs. 2009. PMID: 19262371 Clinical Trial.
Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study.
Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Di Lorenzo G, et al. Among authors: autorino r. Eur Urol. 2011 Dec;60(6):1280-4. doi: 10.1016/j.eururo.2011.08.028. Epub 2011 Aug 22. Eur Urol. 2011. PMID: 21871710 Clinical Trial.
Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
Ferro M, Bruzzese D, Perdonà S, Mazzarella C, Marino A, Sorrentino A, Di Carlo A, Autorino R, Di Lorenzo G, Buonerba C, Altieri V, Mariano A, Macchia V, Terracciano D. Ferro M, et al. Among authors: autorino r. Clin Chim Acta. 2012 Aug 16;413(15-16):1274-8. doi: 10.1016/j.cca.2012.04.017. Epub 2012 Apr 20. Clin Chim Acta. 2012. PMID: 22542564
Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
Perdonà S, Bruzzese D, Ferro M, Autorino R, Marino A, Mazzarella C, Perruolo G, Longo M, Spinelli R, Di Lorenzo G, Oliva A, De Sio M, Damiano R, Altieri V, Terracciano D. Perdonà S, et al. Among authors: autorino r. Prostate. 2013 Feb 15;73(3):227-35. doi: 10.1002/pros.22561. Epub 2012 Jul 20. Prostate. 2013. PMID: 22821756
681 results